Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH
AASLD
NASH
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
EASL International Liver Congress
Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN
Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH
EASL International Liver Congress
